



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009

## SK Biopharmaceuticals

[View the current SK Biopharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/9570-SK+Biopharmaceuticals.html)

(<http://www.bioportfolio.com/biocorporate/9570-SK+Biopharmaceuticals.html>)

### Contact Details:

140 A New Dutch Lane

Fairfield

NJ

07004

United States of America

Tel: 973)227-3939

Fax: 973)227-4488

Email: [dihan@skcorp.com](mailto:dihan@skcorp.com)

SK Biopharmaceuticals, a research and development company specializing in the discovery of small molecule drug candidates and their development from drug target through commercialization will remain in their headquarters in Fairfield, New Jersey. SK Energy & Chemicals, which manufactures and develops fine chemicals, pharmaceutical intermediates, and API's, will remain in their Fair Lawn, New Jersey offices. SK USA is the US headquarters for SK Group, Korea's third largest conglomerate. SK USA develops new business opportunities in the United States through investment activities and provides business support for existing U.S.-based SK companies.

### Press Releases on SK Biopharmaceuticals:

[Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference](#)

24th November, 2009

Keryx Biopharmaceuticals, Inc.

NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the

[NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company](#)

19th November, 2009

NeoStem, Inc.

NEW YORK, Nov. 19 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), announced today that it has sent the following letter to its shareholders, discussing the Company's acquisition, on

<a href="#">Video: Personalized Medicine Drives Multiple Markets, Finds Frost &amp; Sullivan</a>	18th November, 2009	Frost & Sullivan	<i>-- U.S. Molecular Diagnostics Markets for Emerging Infectious Disease Tests In the near future, the firm plans to conduct analyses of additional personalized medicine markets: --</i>
<a href="#">SemBioSys announces third quarter 2009 financial and operational results</a>	13th November, 2009	SemBioSys Genetics Inc.	<i>CALGARY, Nov. 13 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today announced its third quarter 2009</i>
<a href="#">Niusule Announces Key Additions to Management Team</a>	13th November, 2009	Niusule Biotech Corp.	<i>MONROVIA, Calif. and HANGZHOU, China, Nov. 13 /PRNewswire-FirstCall/ -- Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech</i>

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

